| Literature DB >> 22713365 |
Rick Bezemer, Sebastiaan A Bartels, Jan Bakker, Can Ince.
Abstract
A growing body of evidence exists associating depressed microcirculatory function and morbidity and mortality in a wide array of clinical scenarios. It has been suggested that volume replacement therapy using fluids and/or blood in combination with vasoactive agents to modulate macro- and microvascular perfusion might be essential for resuscitation of severely septic patients. Even after interventions effectively optimizing macrocirculatory hemodynamics, however, high mortality rates still persist in critically ill and especially in septic patients. Therefore, rather than limiting therapy to macrocirculatory targets alone, microcirculatory targets could be incorporated to potentially reduce mortality rates in these critically ill patients. In the present review we first provide a brief history of clinical imaging of the microcirculation and describe how microcirculatory imaging has been of prognostic value in intensive care patients. We then give an overview of therapies potentially improving the microcirculation in critically ill patients and propose a clinical trial aimed at demonstrating that therapy targeting improvement of the microcirculation results in improved organ function in patients with severe sepsis and septic shock. We end with some recent technological advances in clinical microcirculatory image acquisition and analysis.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22713365 PMCID: PMC3580600 DOI: 10.1186/cc11236
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Sublingual microcirculation images obtained at the same microcirculatory area using orthogonal polarization spectral imaging (left) and sidestream dark field imaging (right).
Summary of the effects of various interventions on the sublingual microcirculation
| Condition | Number of patients | Intervention | Effects on sublingual | Reference |
|---|---|---|---|---|
| Septic shock | 8 | Nitroglycerin | Increase in MFI | [ |
| Severe sepsis or septic shock | 25 | Fluid therapy with saline or HES | Increase in PVD, PPV, and MFI | [ |
| Decrease in FHI | ||||
| Severe sepsis | 37 | Fluid therapy with RL (n = 16) or HES (n = 21) within 24 h | Increase in TVD, PVD, and PPV | [ |
| 23 | Fluid therapy with RL (n = 13) or HES (n = 10) after 48 h | No changes in TVD, PVD, and PPV | ||
| Post-major gastrointestinal surgery | 45 | Fluid therapy with RS and CS guided by CVP | Decrease in PVD | [ |
| Severe sepsis | 9 | EGDT with HES | At the end of EGDT, PVD, PPV, and MFI were | [ |
| Severe sepsis | 35 | Blood transfusion | Globally no change in microcirculation, but | [ |
| Cardiac surgery | 12 | Blood transfusion | Increase in TVD and PVD | [ |
| Septic shock | 16 | Norepinephrine | No changes in MFI, TVD, PVD, PPV, or FHI | [ |
| Septic shock | 20 | Norepinephrine | Globally no change in microcirculation, but | [ |
| Septic shock | 22 | Dobutamine (intravenous; n = 22) + | Dobutamine increased capillary perfusion, but | [ |
| Sepsis | 35 | Nitroglycerin | No differences in MFI between groups | [ |
| Acute heart failure | 20 | Nitroglycerin | Increase in PVD, which was reversed after | [ |
| Cardiogenic shock | 19 | Nitroglycerin | Dose-dependent increase in PVD | [ |
| Severe sepsis | 20 | Activated protein C | Increase in PPV, which was reversed after | [ |
CS, colloid solution; CVP, central venous pressure; EGDT, early goal-directed therapy; FHI, flow heterogeneity index; HES, hydroxyethyl starch; MFI, microvascular flow index; PPV, proportion of perfused vessels; PVD, perfused vessel density; RL, Ringer's lactate; RS, Ringer's solution; SV, stroke volume; TVD, total vessel density.